{"id":41754,"date":"2023-03-20T14:39:40","date_gmt":"2023-03-20T09:09:40","guid":{"rendered":"http:\/\/finservwealth.com\/divi39s-labs-set-for-big-margin-boost-but-valuations-expensive-says-mofsl\/"},"modified":"2023-03-20T14:39:40","modified_gmt":"2023-03-20T09:09:40","slug":"divi39s-labs-set-for-big-margin-boost-but-valuations-expensive-says-mofsl","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/divi39s-labs-set-for-big-margin-boost-but-valuations-expensive-says-mofsl\/","title":{"rendered":"Divi#39;s Labs set for big margin boost but valuations expensive, says MOFSL"},"content":{"rendered":"<p> The capital expenditure of Rs 2,800 crore incurred at its existing sites would cater to the pharma company\u00e2\u20ac\u2122s growth over the next 12-24 months, while the spend at the Kakinada unit would drive growth beyond FY25, the brokerage firm has said<\/p><div id=\"finse-3756278565\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/divi39s-labs-set-for-big-margin-boostvaluations-expensive-says-mofsl_16933031.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0The capital expenditure of Rs 2,800 crore incurred at its existing sites would cater to the pharma company\u00e2\u20ac\u2122s growth over the next 12-24 months, while the spend at the Kakinada unit would drive growth beyond FY25, the brokerage firm has said The capital expenditure of Rs 2,800 crore incurred at its existing sites would cater to the pharma company\u00e2\u20ac\u2122s growth over the next 12-24 months, while the spend at the Kakinada unit would drive growth beyond FY25, the brokerage firm has said\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/divi39s-labs-set-for-big-margin-boostvaluations-expensive-says-mofsl_16933031.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> The capital expenditure of Rs 2,800 crore incurred at its existing sites would cater to the pharma company\u00e2\u20ac\u2122s growth over the next 12-24 months, while the spend at the Kakinada unit would drive growth beyond FY25, the brokerage firm has said<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/divi39s-labs-set-for-big-margin-boostvaluations-expensive-says-mofsl_16933031.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0The capital expenditure of Rs 2,800 crore incurred at its existing sites would cater to the pharma company\u00e2\u20ac\u2122s growth over the next 12-24 months, while the spend at the Kakinada unit would drive growth beyond FY25, the brokerage firm has said The capital expenditure of Rs 2,800 crore incurred at its existing sites would cater to the pharma company\u00e2\u20ac\u2122s growth over the next 12-24 months, while the spend at the Kakinada unit would drive growth beyond FY25, the brokerage firm has said\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/divi39s-labs-set-for-big-margin-boostvaluations-expensive-says-mofsl_16933031.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> The capital expenditure of Rs 2,800 crore incurred at its existing sites would cater to the pharma company\u00e2\u20ac\u2122s growth over the next 12-24 months, while the spend at the Kakinada unit would drive growth beyond FY25, the brokerage firm has said<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-41754","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2023\/200x200\/D\/Divis-Labs-RnD-Divis-Labs-website_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/41754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=41754"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/41754\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=41754"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=41754"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=41754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}